NorthStar Secures Up to $185 Million Growth Financing Led by Hercules Capital to Scale Actinium-225 Production and Radiopharmaceutical Manufacturing for Next-Generation Precision Cancer Therapies
Hercules Capital (NYSE: HTGC) is leading an up-to-$185 million multi-year growth capital facility for NorthStar Medical Technologies, with $100 million upfront. NorthStar will use the capital to scale commercial production of no-carrier-added Actinium-225 and expand its vertically integrated radiopharmaceutical campus and CDMO in Beloit, Wisconsin.
Key figures
- Deal Value Usd
- $185 million
- Customer count
- more than 30
- Upfront commitment
- $100 million
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.